A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.

COVID-19 SARS-CoV-2 antibodies convalescent plasma efficacy

Journal

Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893

Informations de publication

Date de publication:
11 Apr 2021
Historique:
received: 20 03 2021
revised: 01 04 2021
accepted: 09 04 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 1 5 2021
Statut: epublish

Résumé

COVID-19 is a global pandemic associated with increased morbidity and mortality. Convalescent plasma (CP) infusion is a strategy of potential therapeutic benefit. We conducted a multicenter phase II study to evaluate the efficacy and safety of CP in patients with COVID-19, grade 4 or higher. To evaluate the efficacy of CP, a matched propensity score analysis was used comparing the intervention (

Identifiants

pubmed: 33920489
pii: microorganisms9040806
doi: 10.3390/microorganisms9040806
pmc: PMC8069820
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04408209']

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : No grant.
Pays : United States
Organisme : SYNENOSIS
ID : No grant.

Références

PLoS Med. 2021 Mar 3;18(3):e1003415
pubmed: 33657114
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Theranostics. 2020 Jun 12;10(16):7448-7464
pubmed: 32642005
Transfus Apher Sci. 2020 Oct;59(5):102875
pubmed: 32694043
Hemasphere. 2020 May 21;4(3):e409
pubmed: 32647807
Theranostics. 2021 Jan 1;11(4):1690-1702
pubmed: 33408775
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
J Med Virol. 2020 Oct;92(10):1890-1901
pubmed: 32293713
Saudi J Med Med Sci. 2021 Jan-Apr;9(1):16-23
pubmed: 33519339
Br J Haematol. 2021 Feb;192(4):706-713
pubmed: 33482025
Am J Pathol. 2020 Nov;190(11):2290-2303
pubmed: 32795424
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
Transfus Apher Sci. 2021 Feb;60(1):102955
pubmed: 33011076
J Clin Apher. 2021 Feb 22;:
pubmed: 33616257
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Front Med (Lausanne). 2021 Jan 28;8:630982
pubmed: 33585529
Transfus Apher Sci. 2020 Oct;59(5):102848
pubmed: 32888822
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Immunol Rev. 2015 Nov;268(1):340-64
pubmed: 26497532
Nat Med. 2020 Nov;26(11):1708-1713
pubmed: 32934372
Infez Med. 2020 Sep 1;28(3):357-366
pubmed: 32920571
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
Open Forum Infect Dis. 2021 Jan 04;8(2):ofab001
pubmed: 33604400
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Eur J Clin Microbiol Infect Dis. 2005 Sep;24(9):583-91
pubmed: 16172857
Transfusion. 2020 Oct;60(10):2210-2216
pubmed: 32770691
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Eur Heart J. 2020 May 14;41(19):1858
pubmed: 32227120
Crit Care Med. 2009 May;37(5):1649-54
pubmed: 19325482
Mayo Clin Proc Innov Qual Outcomes. 2021 Apr;5(2):403-412
pubmed: 33585799
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
Haematologica. 2020 Jul 23;105(12):2834-2840
pubmed: 33256382
Int J Infect Dis. 2021 Apr;105:209-215
pubmed: 33607305
JCI Insight. 2021 Mar 22;6(6):
pubmed: 33571168
Clin Microbiol Infect. 2004 Jul;10(7):676-8
pubmed: 15214887
Microorganisms. 2020 Nov 28;8(12):
pubmed: 33260775
Int Immunopharmacol. 2021 Apr;93:107239
pubmed: 33582019
Front Microbiol. 2018 Dec 05;9:2991
pubmed: 30568643
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
RMD Open. 2021 Feb;7(1):
pubmed: 33542047
Blood Cells Mol Dis. 2021 May;88:102548
pubmed: 33621948
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588

Auteurs

Vasiliki Pappa (V)

Hematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.

Anthi Bouchla (A)

Hematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.

Evangelos Terpos (E)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Thomas P Thomopoulos (TP)

Hematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.

Margherita Rosati (M)

Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.

Dimitris Stellas (D)

Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
National Hellenic Research Foundation, Institute of Chemical Biology, 11635 Athens, Greece.

Anastasia Antoniadou (A)

Fourth Department of Internal Medicine, University General Hospital "Attikon", School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Andreas Mentis (A)

National Influenza Reference Laboratory of Southern Greece, Hellenic Pasteur Institute, 11521 Athens, Greece.

Sotirios G Papageorgiou (SG)

Hematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.

Marianna Politou (M)

Hematology Laboratory-Blood Bank, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Anastasia Kotanidou (A)

First Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Ioannis Kalomenidis (I)

First Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Garyfalia Poulakou (G)

3rd Department of Internal Medicine, Sotiria General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Edison Jahaj (E)

First Department of Critical Care Medicine and Pulmonary Services, Evangelismos General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Eleni Korompoki (E)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Sotiria Grigoropoulou (S)

Fourth Department of Internal Medicine, University General Hospital "Attikon", School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Xintao Hu (X)

Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.

Jenifer Bear (J)

Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.

Sevasti Karaliota (S)

Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.
Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.

Robert Burns (R)

Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.

Maria Pagoni (M)

Haematology-Lymphomas Department and BMT Unit, Evangelismos Hospital, 10676 Athens, Greece.

Ioannis Trontzas (I)

3rd Department of Internal Medicine, Sotiria General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Elisavet Grouzi (E)

Transfusion Service and Clinical Hemostasis of Saint Savvas, Oncology Hospital of Athens, 11522 Athens, Greece.

Stavroula Labropoulou (S)

National Influenza Reference Laboratory of Southern Greece, Hellenic Pasteur Institute, 11521 Athens, Greece.

Kostantinos Stamoulis (K)

Hellenic National Blood Transfusion Center, 13678 Athens, Greece.

Aristotelis Bamias (A)

Hematology Unit, Second Propaedeutic Department of Internal Medicine and Research Institute, School of Medicine National and Kapodistrian University of Athens, University General Hospital "Attikon", 18120 Athens, Greece.

Sotirios Tsiodras (S)

Fourth Department of Internal Medicine, University General Hospital "Attikon", School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.

Barbara K Felber (BK)

Human Retrovirus Pathogenesis Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.

George N Pavlakis (GN)

Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA.

Meletios- Athanasios Dimopoulos (MA)

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 11528 Athens, Greece.

Classifications MeSH